Co-targeting epigenetic and oncogenic enzymes in HER2+ breast cancer
M Watanabe - 2022 - search.proquest.com
Breast cancer is the most prevalent cancer worldwide with over 2 million women diagnosed
every year, and caused 685,000 deaths globally in 2020. 15–25% of breast cancer patients …
every year, and caused 685,000 deaths globally in 2020. 15–25% of breast cancer patients …
[HTML][HTML] Inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer
Epigenetic changes are increasingly being appreciated as key events in breast cancer
progression. However, breast cancer subtype-specific epigenetic regulation remains poorly …
progression. However, breast cancer subtype-specific epigenetic regulation remains poorly …
[HTML][HTML] Ezh2, a novel target in detection and therapy of breast cancer
S Pourakbar, TJ Pluard, AD Accurso… - OncoTargets and …, 2017 - Taylor & Francis
In 2013, 232,340 new cases of invasive breast cancer and 39,620 breast cancer deaths
were estimated among US women. 1 Currently, one in eight women in the US will develop …
were estimated among US women. 1 Currently, one in eight women in the US will develop …
[PDF][PDF] EZH2 and cancer progression: An intricate relation that continues to grow
K Kumari, SK Mishra - J Breast Cancer Res, 2020 - probiologists.com
Genetic, epigenetic and environmental factors play disposing role in breast cancer initiation
and progression. Oncogenes and tumor suppressor genes act as molecular players acting …
and progression. Oncogenes and tumor suppressor genes act as molecular players acting …
Selective ezh2 functional activation alters the metastatic landscape of triple negative breast cancer
India is the TNBC capital of the world due to its highest (31%) prevalence and globally it has
huge unmet medical need for its high mortality rate. Aggressive early metastasis is the key …
huge unmet medical need for its high mortality rate. Aggressive early metastasis is the key …
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers
L Blasquez, H Bouzinba‐Segard… - Molecular …, 2023 - Wiley Online Library
Human epidermal growth factor receptor 2 (ErbB2/HER2) is a tyrosine kinase receptor that is
overexpressed in 25% of primary human breast cancers, as well as in multiple other …
overexpressed in 25% of primary human breast cancers, as well as in multiple other …
Activating Mutations in HER2: Neu Opportunities and Neu Challenges
B Weigelt, JS Reis-Filho - Cancer discovery, 2013 - AACR
Twenty-five years after the publication of seminal studies showing that HER2 gene
amplification and protein overexpression are oncogenic in breast cancer, Bose and …
amplification and protein overexpression are oncogenic in breast cancer, Bose and …
[HTML][HTML] Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
N Verschoor, M Smid, A Jager, S Sleijfer… - Breast Cancer …, 2023 - Springer
Background In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a
highly relevant subgroup. However, the exact characteristics which prohibit clinical response …
highly relevant subgroup. However, the exact characteristics which prohibit clinical response …
[HTML][HTML] From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer
M Li, DW Cescon - Canadian Oncology Today, 2024 - canadianoncologytoday.com
The human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth
factor receptor (EGFR) family that initiates various signalling pathways that control cell …
factor receptor (EGFR) family that initiates various signalling pathways that control cell …
[HTML][HTML] Activating HER3 mutations in breast cancer
Recent studies have highlighted a role of HER3 in ER and HER2-driven breast cancers. We
sought to investigate the role of patient-derived HER3 mutations in ER+ and HER2+ breast …
sought to investigate the role of patient-derived HER3 mutations in ER+ and HER2+ breast …